Mutations in the mitochondrial DNA (mtDNA) have been found to be present in several types of tumours including tumours of the large bowel. However, their role in cancer development and prognosis is still to be resolved. We used 2838 cases from a large Scottish colorectal cancer (CRC) case-control study to examine whether inherited genetic variation at the mtDNA influenced allcause and CRC-specific mortality. We examined 140 tagging mtDNA variants including nine haplotypes commonly found in European populations. After applying three Cox proportional hazard models adjusted for American Joint Committee on Cancer (AJCC) stage, age and sex, three single nucleotide polymorphisms, two located in the 12S ribosomal RNA region (G752A and G1440A) and one in the nicotinamide adenine dinucleotide dehydrogenase subunit 2 region (ND2) region (G4770A), were statistically significantly associated with all-cause (Model I P-values: 0.0001, 0.002 and 0.002, respectively) and CRC-specific mortality (Model I P-values: 5 3 10 25 , 0.0003 and 0.0006, respectively). The H and U haplogroups were associated with an increased and decreased CRC risk, respectively, but with P-values of borderline significance and only after AJCC stage adjustment. In conclusion, the findings of the current study suggest a link between three common mtDNA variants and CRC prognosis. These findings are interesting and consistent with other biological knowledge but need to be confirmed through replication in independent cohorts.
Introduction
Survival rates of colorectal cancer (CRC) have been improved the last 25 years, CRC deaths still account for $10% of all cancer deaths in the UK (Cancer Research UK, 2005). The main CRC prognostic marker is stage at diagnosis, which describes tumour spread through the bowel wall, number of affected lymph nodes and spread of tumour to distant organs (metastasis) (1) . Some studies have reported that lifestyle factors such as physical activity and body mass index influence particular characteristics of the tumour systemic inflammatory response (2, 3) . There is evidence of familial concordance for survival to a number of cancers, including CRC, which suggests that inherited genetic variation can contribute to CRC prognosis (4) . Finally, a few studies have investigated the survival effect of genetic variants alone (5) or in combination with particular treatments (6, 7) . In addition, a recent study that investigated the survival effect of common variants and haplotypes of the mismatch repair genes concluded that there is some evidence these variants may contribute to survival of CRC patients (1) .
Mitochondrial DNA (mtDNA) is a double-stranded circular genome of $16.5 kb in length. It contains a highly mutagenic noncoding region [the displacement loop (D-loop)], a coding region of 37 genes that encode for proteins that are all part of the respiratory chain complex, and 22 transfer RNAs and 2 ribosomal RNAs (rRNAs) which are required for protein synthesis in the mitochondrion (8) . Since every cell contains many hundreds of mitochondria, hundreds of copies of mtDNA are found in each cell. Mutations that occur in the mtDNA may therefore affect only some of the mtDNA copies, a phenomenon called heteroplasmy, and the phenotype is determined by the predominant mtDNA variant.
Mitochondria are the main sites of reactive oxygen species generation, which causes oxidative stress and DNA damage in the mitochondria. Indeed, mtDNA has been found to have a higher mutation rate than nuclear DNA (8) and findings from several studies suggest that mitochondrial genome might have an effect on carcinogenesis (9) . However, two recent studies, one investigating the association between 132 common mtDNA variants and CRC risk and one investigating the association between 24 mtDNA variants and prostate risk found no evidence of a link between mtDNA and cancer risk (10, 11) .
Regarding CRC prognosis, no comprehensive investigation of the association between CRC prognosis and mtDNA has been conducted and studies are limited to mutations of the D-loop mtDNA region. Therefore, in the current study, we genotyped 180 tagging mtDNA variants in order to evaluate their association with all-cause or CRCspecific mortality. In addition, we investigated whether there is a link between nine haplotypes commonly found in European populations and all-cause or CRC-specific mortality.
Methods

Description of sample sets
The study included cases of Scottish ancestry (defined as parents and all grandparents residing in Scotland) from a population-based case-control study of CRC (Study of Colorectal Cancer in Scotland; 1999-2006) (12) . Ethical approval was obtained from the MultiCentre Research Ethics committee for Scotland, 18 Local Research Ethics committees, 18 Caldicott guardians and 16 National Health Service Trust management committees, and all participants provided written informed consent.
Cases were recruited soon after a confirmed diagnosis of adenocarcinoma of large bowel epithelium, to minimize survival bias. Participation rate among the approached cases was 52% (3471 CRC cases) and 98.4% of the recruited cases were finally included in the Study of Colorectal Cancer in Scotland (3417 CRC cases). The current analysis was part of our Genome Wide Association Scan for colorectal cancer risk. Dominant polyposis syndromes, hereditary nonpolyposis colorectal cancer or bi-allelic MYH mutation carriers were not included in the Genome Wide Association Scan analysis. Genetic data were available for 3017 CRC cases (supplementary Figure 1 is available at Carcinogenesis Online). Cases were excluded from the survival analysis for the following reasons: not enough DNA for DNA amplification (43 cases); genotyping failure (one case); previously unrecognized carriers of another susceptibility allele (five cases); gender discrepancies between our records and genotype (10 cases); date of diagnosis a year prior to study's initiation date (six cases); missing data [American Joint Committee on Cancer (AJCC): 98 cases and date of diagnosis: 14 cases] and duplicates (two cases). Therefore, 2838 cases were included in the survival analysis of common mtDNA variants (supplementary Figure 1 is available at Carcinogenesis Online).
Genotyping, quality control and variant selection Three aliquots of 10 ml of blood were collected from each case in one acid citrate dextrose and two sodium ethylenediaminetetraacetic acid tubes. One ethylenediaminetetraacetic acid sample was directly extracted to DNA using Nucleon kits. Median DNA yield on samples was 327 lg (range: 50-1197 lg).
Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; CRC, colorectal cancer; D-loop, displacement loop; FPRP, falsepositive report probability; MAF, minor allele frequency; mtDNA, mitochondrial DNA; NADH, nicotinamide adenine dinucleotide dehydrogenase; rRNA, ribosomal RNA; SNP, single nucleotide polymorphism.
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Quality control procedures included spectrophotometric readings of every sample (either A260/280 or PicoGreen TM ), agarose gel electrophoresis of uncut and restriction enzyme-cut DNA from 2% of samples and a control polymerase chain reaction on 1% of samples (13) .
The mtDNA variants were genotyped using a custom made Illumina array. Methods of this as well as information regarding the measures taken to ensure the genotyping quality were described in detail previously (13) . Briefly, in Phase 1, 1012 cases (aged 56 years old) were genotyped using Illumina HumanHap300 and HumanHap240S arrays on the Infinium platform. In phase 2, 2037 cases (aged ,80 years old) were genotyped using the Illumina iSelect custom panel for the top 15 008 single nucleotide polymorphisms (SNPs) that were strongly associated with CRC risk. In addition, phase 2 cases were genotyped for a larger mtDNA SNPs set than that included in the HumanHap240S array. This larger set was selected as described below in order to screen the whole mtDNA. In both Phases 1 and 2, samples were distributed randomly and blinded to survival status within 96-well sample plates to minimize systematic genotyping bias due to batch-to-batch variations. Genotype call rates were high for both the HumanHap300 (99.92%) and HumanHap240S (99.85%) arrays. (13) .
The variant selection was based on a recent study that identified: (i) 144 variants of .1% minor allele frequency (MAF) that are common in European population and (ii) a set of 64 SNPs that tag all common mtDNA variants (r 2 .0.8) (14) . According to this information and by taking into account the designability of the genotyping platform, 180 variants were included in Phase 2. One hundred and forty SNPs were successfully genotyped, 97 of which were also included in Phase 1. Variants of the D-loop region were excluded since this region is associated with high mutation rates, which cannot be successfully addressed by array genotyping. In addition to individual mtDNA variants, the previously described haplogroups H, I, J, K, T, U, V, W and X, which are common in European populations were tested and their classification is presented in supplementary table 1 (available at Carcinogenesis Online) (10) .
Survival analysis
The 2838 cases that were included in the survival analysis were observed until death or 30th of April 2008 (censored date), whichever came first. For 2771 CRC cases (97.6%), date of diagnosis (incidence date) was provided by Scottish Cancer Registry and for 67 CRC cases (2.4%), it was extracted from their first pathology report (collected at recruitment). Death certificates were provided by the General Register Office for Scotland. There were 947 deaths from the start of recruitment to censored date. The cause of death was determined by a physician examining all death certificates and there were 811 deaths that were due to CRC (86% of all deaths). The protocol devised for deciding whether the death was CRC related is available upon request. Participants were linked to Scottish Cancer Registry and General Register Office through the Community Health Index, which is an National Health Service population-based register of all individuals who are registered with a general practitioner in Scotland (95% completeness) (15) .
To determine the cancer stage according to the AJCC system, the following procedure was followed. For patients from the South East Scotland (South East Scotland Cancer Network region) computerized tomography scans were requested and individually checked for evidence of metastasis. For patients from the West and North of Scotland (West of Scotland Cancer Network and North of Scotland Cancer Network regions, respectively), the consultants of individual patients were contacted by letter requesting staging information and clarification of metastasis status for their patients. For the remaining cases, individual General Practitioners were contacted by letter. The stage distribution for South East Scotland Cancer Network, West of Scotland Cancer Network and North of Scotland Cancer Network was not statistically significantly different (chi-square test P-value 0.17). In addition, the mean survival time in the different regions of Scotland was similar (between 4.2 and 4.8 years).
Variants with a MAF of ,1% were excluded from the analysis. Survival analysis of each individual SNP (MAF .1%) and haplotype was performed using the G12BAF routine of the numerical algorithms group library (FOR-TRAN) and the statistical package Intercooled STATA version 10.0 (StataCorp LP, College Station, TX). The t-test was used to test differences in mean age and the Pearson chi-square test was used to test differences in terms of sex and AJCC status between deceased and survived/censored cases. Cox proportional hazards models were used to calculate hazards ratios between mtDNA variants or haplotypes and death adjusted for other risk factors: Model I (adjusted for AJCC, age and sex), Model II (adjusted for age and sex) and Model III (crude model). In the first analysis, death from any cause was the end point, whereas in the second analysis death from CRC was the end point with deaths from other causes being treated as censored. The proportional hazards assumption was checked by fitting a model including time-dependent covariates on the exposures and testing if the time-dependent covariates are significant.
False-positive report probability
The false-positive report probability (FPRP) is defined as 'the probability of no association given a statistically significant P-value' (16). The factors that determine the magnitude of the FPRP are as follows: (i) the prior probability of the true association between the variant and the disease, (ii) the observed P-value and (iii) the statistical power to detect the effect size of the alternative hypothesis given the observed P-value (16). For variants and haplogroups that were found to be statistically significantly associated both with all-cause and CRC-specific mortality (for all three models), the FPRP was estimated using the Excel FPRP calculation spreadsheet (http://jnci.oxfordjournals.org/cgi/ content/full/96/6/434/DC1). We chose to calculate FPRP values for three levels of prior probabilities: at a medium/low prior level (0.05/0.001) that would be close to what would be expected for a candidate gene and at a very low prior level (10 À6 ) that would be close to what would be expected for a random SNP. The statistical power was estimated based on the ability to detect an odds ratio of 1.5 and 1.2 at an a level equal to the observed P-value. Finally, the FPRP threshold for noteworthiness was set up to be equal to 0.20.
Results
One hundred and forty of the 180 selected tagging variants were successfully genotyped (77.8%). Of these 140, 17 monomorphic variants (12.2%) and 52 with a MAF of ,0.01 (37.1%) were removed from the analysis, leaving 71 SNPs (50.7%) valid for analysis. We compared the 64 tagging SNPs reported by Saxena et al. (14) with the 140 variants that were successfully genotyped in our population (supplementary table 2 is available at Carcinogenesis Online). In total, 46.9% (30/64) of the Saxena tagging SNPs were successfully genotyped in our population, but five of them were either monoallelic or their MAF was ,0.01. For 19 (29.7%) of the remaining 34 Saxena tagging SNPs that were not directly genotyped, at least one of their tagged SNPs (as reported in Saxena) was successfully genotyped in our population, but four of them were either monoallelic or their MAF was ,0.01. Finally, 23.4% (15/64) of the tagging or their tagged SNPs were not genotyped in our population (supplementary table 2 is available at Carcinogenesis Online).
Data for 14 of the 71 mtDNA variants and six of the nine haplogroups (H, I, J, T, V and X) were available only for phase 2 cases (n 5 1939). In Table I summary statistics of the confounding factors for the phase 1 and 2 cohort as well as separately for the phase 2 cohort are presented. AJCC stage was strongly associated (chi-square test P-value: ,5 Â 10 À7 ) with all-cause and CRC-specific mortality in both cohorts (phase 1 and 2 and phase 2). Age was associated with all-cause mortality in the phase 2 cohort and with CRC-specific mortality in the phase 1 and 2 cohort (t-test P-value: 0.0002 and 0.02, respectively). Finally, sex was associated with all-cause mortality in the phase 2 cohort (chi-square test P-value: 0.01) ( Table I) .
General information of the survival analysis, including the numbers at risk (at selected time points), numbers of events at selected time points and follow-up information, is presented in supplementary table 3 (available at Carcinogenesis Online). After applying Model I (adjusted for AJCC, age and sex), seven SNPs were associated with all-cause mortality (P-value level of significance ,0.1): G752A (P 5 0.0001), G1440A (P 5 0.002), G4770A (P 5 0.002), T14767C (P 5 0.02), G2708A (P 5 0.03), G12373A (P 5 0.08) and C464T (P 5 0.09) ( Table II) . Six of these SNPs were associated with CRC mortality too: G752A (P 5 5 Â 10 À5 ), G1440A (P 5 0.0003), G4770A (P 5 0.0006), G12373A (P 5 0.04), G2708A (P 5 0.05) and T14767C (P 5 0.08) (Table II) and two SNPs were associated only with CRC-specific mortality (P-value level of significance ,0.1): A11468G (P 5 0.08) and A12309G (P 5 0.07) (Table II) . Results after applying models II and III were similar to the ones from Model I (supplementary tables 4 and 5 is available at Carcinogenesis Online). In summary, the variants that were found to be associated with all-cause and CRC-specific mortality in all three models were G752A, G1440A and G4770A (Table II,  supplementary tables 4 and 5, supplementary figures 2 and 3 available at Carcinogenesis Online).
Results of the haplogroup analysis (Model I) are presented in Tables III and IV. The haplogroup H was associated with an increased all-cause and CRC-specific mortality (P-value 0.02 and 0.07, respectively) after applying Model I. In addition, the haplogroup U was associated with a decreased all-cause and CRC-specific mortality Association between mtDNA and CRC (P-value 0.08 and 0.08, respectively), after applying Model I (Tables  III and IV) . However, none of the haplogroups were statistically significantly associated with all-cause or CRC-specific mortality after applying Models II and III (supplementary tables 6 and 7, supplementary figures 4 and 5 available at Carcinogenesis Online).
We fitted a model including time-dependent covariates on the exposures to check the proportional hazards assumption. The assumption was true for the SNP/haplogroup, age and sex covariates but not for the AJCC covariate. For the SNPs that were found to be statistically significant, we therefore rerun Model I stratified by stage (AJCC 1 and 2 and AJCC 3 and 4). The results did not change significantly the effect of the G752A. The effect of the G1440A and G4770A remained statistically significant only for the AJCC 3 and 4. However, the hazards ratios for the AJCC 1 and 2 were not significantly different from the hazards ratios for the AJCC 3 and 4 or from the estimates obtained after adjusting for AJCC (supplementary table 8 is available at Carcinogenesis Online).
We calculated FPRP values to test the robustness of the findings for the following mtDNA variants: G752A, G1440A and G4770A (supplementary table 9 is available at Carcinogenesis Online). None of the findings of the haplotype analysis was tested since statistically significant associations were observed only for Model I. At a prior probability level of 0.05 and statistical power to detect an odds ratio of 1.5, associations between G752A, G4770A and all-cause mortality and associations between G752A, G1440A, G4770A and CRC-mortality remained noteworthy (FPRP ,0.2). However, at all other prior probabilities (0.01-10 À6 ) and at statistical power to detect both an odds ratio of 1.5 and 1.2, all associations had FPRP values higher than the 0.2 threshold (supplementary table 9 is available at Carcinogenesis Online).
Discussion
The role of the mtDNA mutations both in carcinogenesis and prognosis is still to be established. Results regarding the effect of mtDNA variants on CRC carcinogenesis are inconclusive with the most recent studies reporting no large effect of mtDNA common variants on cancer risk (10, 11) . However, this might be due to lack of power (falsenegative results) or there might be rarer mtDNA variants associated with CRC risk. Alternatively, it is possible that mtDNA mutations do not affect carcinogenesis but are involved in a later stage of cancer progression affecting cancer prognosis (for example by influencing the risk of metastasis) (17) . A recent study of 990 pancreatic cancer cases reported that there was no association between 24 mitochondrial SNPs or haplogroups and pancreatic cancer prognosis (18) . Two studies have previously investigated whether mutations in the D-loop mtDNA region are linked to a poor CRC prognosis (9,19). In (19) .
Main findings
In the current analysis, we investigated whether common mtDNA variants and nine haplogroups commonly found in European populations were associated with all-cause or CRC-specific mortality. The associations between mtDNA SNPs and all-cause mortality were similar to the associations between mtDNA SNPs and CRC mortality. We found that G752A (located in the 12S rRNA region), G1440A (located in the 12S rRNA) and G4770A [located in the nicotinamide adenine dinucleotide dehydrogenase (NADH) subunit 2 region-ND2] were statistically significantly associated both with all-cause and CRCspecific mortality in all three models applied (Model I all-cause mortality P-values: 0.0001, 0.002 and 0.002, respectively; Model I CRC-specific mortality P-values: 5 Â 10 À5 , 0.0003 and 0.0006, respectively). Two haplogroups H and U were associated with an increased and decreased all-cause mortality and CRC mortality risk, respectively, with P-values of borderline significance and only after AJCC stage adjustment. Both haplogroups contained SNPs that were found to be associated with CRC in the AJCC adjusted model (T14767C and A12309G, respectively).
12S rRNA variants
To our knowledge, no studies have investigated whether 12S rRNA mutations affect cancer progression. However, 12S rRNA mutations have been hypothesized to affect carcinogenesis by influencing cell apoptosis. In particular, three somatic point mutations (MAF 2%) in the 12S rRNA region have been linked to endometrial cancer (based on the genotyping of mtDNA of 50 cancer tissues and their normal controls) (20) In addition, analysis of 10 ovarian cancer tissues and their normal controls identified two somatic mutations in the 12S rRNA region (21) . Finally, a study of 19 paired tumour-normal prostate samples reported that gene expression of the mitochondrial 12S rRNA is lower in tumour when compared with normal samples (22) .
NADH dehydrogenase subunit 6 (ND6) variants
A recent study based on cytoplasmic hybrid technology in a mouse tumour cell line reported that mtDNA containing mutations in the NADH dehydrogenase subunit 6 (ND6) region affected the metastatic potential of the tumour cells but had no effect on cancer development. It was also shown that the main effect of these mutations was a defect in the respiratory complex I activity leading to overproduction of reactive oxygen species (17) . The association between G4770A, located in the ND2 and mortality might therefore be due to a similar defect of the respiratory complex I. After calculating the FPRP for prior probabilities ranging from 0.01-10 À6 , these associations were not noteworthy at a threshold level of 0.2. Therefore, further studies should be conducted to attempt to replicate these findings and so determine whether the current findings represent true-or false-positive results.
Strengths and limitations
The strengths of this study include the systematically and prospectively collected dataset of CRC cases and therefore being representative of the general population. In addition, data relevant to the survival analysis were of high quality since they were obtained from the Scottish registries General Register Office and Scottish Cancer Registry after linkage of our participants with their databases (using the Community Health Index number). In addition, extra care was taken in order to determine the AJCC cancer stage by looking at individual computerized tomography and by requesting staging and metastasis information by individual consultants and general practitioners. Limitations of our study include under-representation of cases that were very ill at presentation and therefore possible limiting the external validity of results for CRC patients of advanced AJCC stage. In addition, not all of the 64 tagging SNPs identified by Saxena et al. (14) were successfully genotyped and had an MAF of .1% in our population. Also, it was not possible to address heteroplasmy in our study due to limitations of the analytical platform. Additionally, mitochondrial SNPs are more prone to false-positive results than genomic SNPs due to population stratification because haplogroups vary widely across human populations (23, 24) . However, our samples were selected from across Scotland and subjects reported the origin of their grandparents to be Scottish. We also performed extensive quality control procedures based on our genomic SNPs and found no evidence for population stratification. Overall, this suggests that the possibility of an increased type I error rate due to population stratification is minimal. Finally, treatment differences between hospitals may have affected survival. However, treatment of CRC is generally standardized in Scotland using the Scottish Intercollegiate Guidelines Network (http://www.sign.ac.uk/). The objective of Scottish Intercollegiate Guidelines Network is to improve the quality of health care for patients in Scotland by reducing variation in practice and outcome. Therefore, it is expected that treatment differences between hospitals will be small and will not affect survival especially if there is a genetic predisposition for a better or worse prognosis.
Conclusion
In conclusion, we investigated the association between 71 polymorphic mtDNA variants, 9 haplogroups common in European populations and mortality (all cause and CRC specific). We identified three SNPs, two located in the 12S rRNA region (G752A and G1440A) and one in the ND2 region (G4770A), that were statistically significantly associated with all-cause and CRC-specific mortality in all three Cox proportional hazard models. 12S rRNA region was previously found to be linked with some types of cancer whereas ND6 region was recently found to affect the metastatic potential of mouse cancer cell lines. However, since the calculated FPRP values were above our set threshold level, these findings though interesting and plausible might be false-positives and therefore replication analysis in other populations is necessary.
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